Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...
Clinical Trials Arena on MSN3d
Palatin’s UC therapy prompts clinical remission in a third of patientsA third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug ...
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback